---
title: "Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/272130852.md"
datetime: "2026-01-09T23:01:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272130852.md)
  - [en](https://longbridge.com/en/news/272130852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272130852.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/272130852.md) | [繁體中文](https://longbridge.com/zh-HK/news/272130852.md)


# Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program

Ascendis Pharma A/S has outlined its strategic roadmap for 2026, focusing on expanding its global biopharma presence. Key future plans include accelerating global penetration and commercial expansion, anticipating a potential third TransCon product approval with blockbuster potential, and advancing a pipeline of differentiated TransCon product candidates. The company expects continued growth driven by its TransCon technology platform, R&D capabilities, and maturing commercial infrastructure. Financial initiatives include a planned $120 million share repurchase program, with flexibility in execution based on market conditions. Ascendis Pharma’s leadership emphasized these goals during a presentation at the 44th Annual J.P. Morgan Healthcare Conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623218-en) on January 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相关股票

- [Ascendis Pharmac (ASND.US)](https://longbridge.com/zh-CN/quote/ASND.US.md)

## 相关资讯与研究

- [Ascendis Wins FDA Approval For Rare Disease Therapy](https://longbridge.com/zh-CN/news/277469221.md)
- [Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today](https://longbridge.com/zh-CN/news/269778261.md)
- [Nitto Denko Corporation authorizes a Buyback Plan.](https://longbridge.com/zh-CN/news/281052235.md)
- [BASF Pharma Solutions announces global price adjustment for pharmaceutical excipients and selected APIs](https://longbridge.com/zh-CN/news/281006696.md)
- [Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/zh-CN/news/280971196.md)